Zentalis Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 9 analysts polled by S&P Global, Zentalis Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $6.50. The average 1-year stock price forecast is 84.66% higher than the current stock price, while the lowest is $4.00 (+13.64%) and the highest is $10 (+184.09%).

Price Target: $6.50 (+84.66%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$4.00	$6.50	$5.50	$10
Change	+13.64%	+84.66%	+56.25%	+184.09%

Analyst Ratings

The average analyst rating for Zentalis Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Nov '25	Jan '26	Feb '26	Mar '26	Apr '26	May '26
Strong Buy	4	4	4	4	4	3
Buy	0	0	0	0	0	0
Hold	5	5	5	5	5	5
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	9	9	9	9	9	8

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Andres Y. Maldonado H.C. Wainwright	H.C. Wainwright	Buy Maintains $10	Buy	Maintains	$10	+184.09%	May 26, 2026
Unknown Analyst Wedbush No rating	Wedbush	Hold Maintains $4	Hold	Maintains	$4	+13.64%	May 13, 2026
Michael Ulz Morgan Stanley	Morgan Stanley	Hold Maintains $4	Hold	Maintains	$4	+13.64%	May 13, 2026
Matthew Biegler Oppenheimer	Oppenheimer	Buy Reiterates $9	Buy	Reiterates	$9	+155.68%	May 13, 2026
Eva Fortea Verdejo Wells Fargo	Wells Fargo	Hold Reiterates $5	Hold	Reiterates	$5	+42.05%	May 13, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

21.42M

EPS This Year

-1.74

from -1.80

EPS Next Year

-1.56

from -1.74

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	-	-	67.43M	-	-
Gross Profit	-	-	-	67.43M	-	-
Gross Margin	-	-	-	100.00%	-	82.00%
Operating Income	-207.74M	-227.29M	-248.99M	-187.46M	-140.88M	-160.42M
Net Income	-158.73M	-236.81M	-292.19M	-165.84M	-137.06M	-150.13M
EPS	-	-	-	-	-1.80	-1.74
Free Cash Flow	-89.16M	-88.02M	-86.97M	-67.10M	-75.87M	-157.47M
No. Analysts	-	-	-	-	-	8

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	n/a
Avg	n/a
Low	n/a

Revenue Growth

Revenue Growth	2027	2028
High	-
Avg	-
Low	-

EPS Forecast

EPS	2026	2027	2028
High	-1.33
Avg	-1.74
Low	-2.19

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-